Literature DB >> 23523636

Mislocalised FUS mutants stall spliceosomal snRNPs in the cytoplasm.

Valeria Gerbino1, Maria Teresa Carrì, Mauro Cozzolino, Tilmann Achsel.   

Abstract

Genes encoding RNA-binding proteins have frequently been implicated in various motor neuron diseases, but the particular step in RNA metabolism that is vulnerable in motor neurons remains unknown. FUS, a nuclear protein, forms cytoplasmic aggregates in cells affected by amyotrophic lateral sclerosis (ALS), and mutations disturbing the nuclear import of FUS cause the disease. It is extremely likely that the cytoplasmic aggregates are cytotoxic because they trap important factors; the nature of these factors, however, remains to be elucidated. Here we show that FUS associates in a neuronal cell line with SMN, the causative factor in spinal muscular atrophy (SMA). The two genes work on the same pathway, as FUS binds to spliceosomal snRNPs downstream of the SMN function. Pathogenic FUS mutations do not disturb snRNP binding. Instead, cytoplasmic mislocalisation of FUS causes partial mis-localisation of snRNAs to the cytoplasm, which in turn causes a change in the behaviour of the alternative splicing machinery. FUS, and especially its mutations, thus have a similar effect as SMN1 deletion in SMA, suggesting that motor neurons could indeed be particularly sensitive to changes in alternative splicing.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23523636     DOI: 10.1016/j.nbd.2013.03.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  36 in total

Review 1.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

Review 2.  Developing therapies for spinal muscular atrophy.

Authors:  Mary H Wertz; Mustafa Sahin
Journal:  Ann N Y Acad Sci       Date:  2015-07-14       Impact factor: 5.691

3.  FUsed in sarcoma is a novel regulator of manganese superoxide dismutase gene transcription.

Authors:  Sanjit Kumar Dhar; Jiayu Zhang; Jozsef Gal; Yong Xu; Lu Miao; Bert C Lynn; Haining Zhu; Edward J Kasarskis; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2013-09-20       Impact factor: 8.401

Review 4.  Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions.

Authors:  Julia K Nussbacher; Ricardos Tabet; Gene W Yeo; Clotilde Lagier-Tourenne
Journal:  Neuron       Date:  2019-04-17       Impact factor: 17.173

5.  Nuclear localization of SMN and FUS is not altered in fibroblasts from patients with sporadic ALS.

Authors:  Shingo Kariya; Jacinda B Sampson; Lesley E Northrop; Christopher M Luccarelli; Ali B Naini; Diane B Re; Michio Hirano; Hiroshi Mitsumoto
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-05-09       Impact factor: 4.092

Review 6.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

Review 7.  RNA binding proteins: a common denominator of neuronal function and dysfunction.

Authors:  Epaminondas Doxakis
Journal:  Neurosci Bull       Date:  2014-06-24       Impact factor: 5.203

Review 8.  RNA-binding proteins implicated in neurodegenerative diseases.

Authors:  Mark R Cookson
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-09-23       Impact factor: 9.957

9.  Minor intron splicing is regulated by FUS and affected by ALS-associated FUS mutants.

Authors:  Stefan Reber; Jolanda Stettler; Giuseppe Filosa; Martino Colombo; Daniel Jutzi; Silvia C Lenzken; Christoph Schweingruber; Rémy Bruggmann; Angela Bachi; Silvia Ml Barabino; Oliver Mühlemann; Marc-David Ruepp
Journal:  EMBO J       Date:  2016-06-01       Impact factor: 11.598

Review 10.  FUS-mediated alternative splicing in the nervous system: consequences for ALS and FTLD.

Authors:  Denise Orozco; Dieter Edbauer
Journal:  J Mol Med (Berl)       Date:  2013-08-24       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.